In vitro precise simulation method of inflammatory bowel disease and fibrosis
Through macrophage-inclusive colonic organoids and TGF-β induction technology, rapid and accurate in vitro simulation of inflammatory bowel disease and fibrosis are achieved, solving the accuracy problems caused by the lack of macrophages in existing models and providing high efficiency disease research tools.
Patent Information
- Application Number
- CN202410831188.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-06-26
AI Technical Summary
The existing in vitro model of inflammatory bowel disease (IBD) lacks macrophages and cannot accurately simulate the inflammatory response and fibrosis process, which limits the accuracy and application value of the model.
Macrophage-containing colonic organoids combined with TGF-β inducer were used to gradually induce IBD and fibrotic phenotypes through multi-dimensional indicators to achieve rapid (within 4 days) and accurate in vitro simulation.
Induce inflammatory response and IBD pathological phenotype within 48 hours and progress to fibrosis within 4 days, presenting serum marker elevation and collagen deposition, providing a rapid multi-scale pathological simulation tool with a human genetic background, suitable for disease Analysis and efficacy screening.
Smart Images

Figure CN118389408B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of induced pluripotent stem cells, and in particular to a method for accurately simulating inflammatory bowel disease and fibrosis in vitro. Background Art
[0002] Due to the complexity of IBD (inflammatory bowel disease), the pathological mechanism of IBD is still unclear. Deeply revealing the disease mechanism and developing more effective treatment strategies are the only way to achieve a complete cure for IBD. Among them, as a basic tool for pathological analysis and drug development, the disease model of IBD plays a key role.
[0003] Since it is difficult to obtain primary human intestines, IBD-related research has long used rodents as the main model (such as mice, rats, etc.). However, due to different genetic backgrounds, these models differ greatly from humans in terms of physiology and even IBD pathology, and have obvious limitations. As an emerging in vitro 3D model, organoids are diverse in lineage and rich in functions. They not only overcome the shortcomings of traditional 2D cell models in physiological relevance, but also have the advantage of being humanized. They are expected to be further developed into a new generation of IBD in vitro disease models. At present, most organoid-based IBD models only contain epithelial cell types and lack macrophages, a key cell type in the development of IBD; therefore, they cannot simulate inflammatory responses and their associated various pathological characteristics, limiting the accuracy of the model. Summary of the invention
[0004] In view of this, the present invention aims to provide a method for precise in vitro simulation of inflammatory bowel disease and fibrosis. This method combines macrophage-containing colon organoids with the inducer TGF-β to obtain IBD and fibrosis phenotypes in vitro for the first time quickly (within 4 days) and accurately (progressive induction + multi-dimensional indicators).
[0005] To achieve the above object, the technical solution of the present invention is implemented as follows:
[0006] An in vitro precise simulation method for inflammatory bowel disease and fibrosis, the method comprising the following steps:
[0007] 1) Construction of macrophage-containing colon organoids
[0008] Induce pluripotent stem cells to differentiate into the middle and posterior derivatives of the intestinal tube with hematopoietic progenitor cells, then select the lower layer 2D cells for mechanical disruption, and then encapsulate them in Matrigel and use medium 3a and medium 3b to continue differentiation to form colon organoids;
[0009] The obtained organoids were then transferred to EP tubes and mechanically broken, and then coated with matrix gel again, and then pre-cultured with culture medium 3a, and then continued to be cultured with culture medium 3b, and subcultured every 7-10 days, and pre-cultured for each subculture; the expanded and cultured organoids were then tested to verify that the organoids had both colon epithelial cells, mesenchymal cells and intestinal resident macrophages, and the inflammation-mediating function of macrophages was verified;
[0010] 2) Inflammatory bowel disease and fibrosis simulation
[0011] 2.1) IBD simulation
[0012] Use TGF-β to induce the organoids obtained in step 1) for 48-72 hours, and perform IBD pathological phenotype analysis on the organoids to verify the IBD model;
[0013] 2.2) Fibrosis simulation
[0014] After continuous induction for 96-120 hours, the organoids were analyzed for fibrosis pathological phenotype to verify the obtained fibrosis model.
[0015] Furthermore, in step 1), the organoids are characterized by flow cytometry or immunofluorescence staining to confirm lineage diversity.
[0016] Furthermore, in step 1), the method for verifying the inflammatory mediating function of macrophages is: after stimulating the organoids with 200 ng / ml LPS for 24 hours, the secretion of inflammatory factors in the supernatant is measured by ELISA.
[0017] Furthermore, the inflammatory factors include one or more of IL-23, IL-6, TNF-α, and IL-1β.
[0018] Furthermore, the concentration of TGF-β is 2-10 ng / ml.
[0019] Furthermore, the IBD pathological phenotype includes one or more of the following indicators: macrophage polarization, increased inflammation level, decreased mucus content, enhanced epithelial-mesenchymal transition, and impaired intestinal barrier;
[0020] The fibrotic pathological phenotype includes one or two of the following indicators: ECM accumulation and increased serum fibrosis markers.
[0021] Furthermore, macrophage polarization can be analyzed by flow cytometry to detect M1 macrophage markers, such as CD86 and CD80;
[0022] Increased inflammation levels can be analyzed by measuring inflammatory factors such as IL-23, IL-6, TNF-α, IL-1β, etc. through ELISA;
[0023] Reduced mucus content can be analyzed by PAS mucus staining and ELISA for MUC2;
[0024] The aggravation of epithelial-mesenchymal transition can be analyzed by quantitative PCR or immunostaining for epithelial markers such as ECAD and β-CAT, and mesenchymal markers such as VIM and DES;
[0025] Intestinal barrier damage can be detected by barrier permeability experiments or fluorescence quantitative PCR analysis of channel protein markers such as CLDN.
[0026] Furthermore, ECM accumulation can be analyzed by quantitative fluorescence PCR or immunostaining for one or more of the markers α-SMA, COL1A1 / 3, FN1, PDGFRα / β, and MYLK;
[0027] Elevated serum markers of fibrosis can be measured by ELISA for the marker PIIINP.
[0028] Further, in step 1), the organoids are pre-cultured in culture medium 3a for 1-2 days after mechanical disruption; culture medium 3a includes BMP2, EGF, Wnt / β-CAT activator and StemPro-34, and culture medium 3b includes EGF, BMP inhibitor, Wnt / β-CAT activator, VEGF, M-CSF and StemPro-34.
[0029] Furthermore, the concentration of BMP2 was 50-150 ng / ml, the concentration of EGF was 50-150 ng / ml, the concentration of Wnt / β-CAT activator was 2-4 μM, the concentration of BMP inhibitor was 100-250 nM, the concentration of VEGF was 10-20 ng / ml, and the concentration of M-CSF was 10-20 ng / ml; the volume ratio of StemPro-34 in culture medium 3a was 21.25%-42.5%, and the volume ratio in culture medium 3b was 17.5-35%.
[0030] Compared with the prior art, the in vitro precise simulation method of inflammatory bowel disease and fibrosis described in the present invention has the following advantages:
[0031] The in vitro precise simulation method of inflammatory bowel disease and fibrosis described in the present invention comprises the following steps: induction and differentiation of macrophage-containing colon organoids, passage expansion and quality inspection of amplified products, TGF-β induced modeling, and in vitro simulation of inflammatory bowel disease and fibrosis. This method can induce a series of IBD pathological phenotypes such as macrophage polarization, inflammatory response, epithelial-mesenchymal transition, barrier damage, etc. within 48 hours; and progress to fibrosis within 4 days, showing clinical pathological characteristics such as elevated serum markers and collagen deposition. This disease model not only has a human genetic background, but also can quickly realize multi-scale pathological simulation of IBD, and is suitable as a new generation of research tools for disease analysis and drug efficacy screening. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:
[0033] Figure 1 It is a technical flow chart;
[0034] Figure 2 To identify the major lineage types of the amplicon, the cellularity of P3 colon organoid samples was analyzed by flow cytometry; SATB2 + A marker for colon epithelial cells; MUC2 + Goblet cell marker; VIM + A mesenchymal cell marker; CD68 + It is a macrophage marker; duplicate wells n=4;
[0035] Figure 3 For macrophage inflammation-mediated function assay; A is ELISA to detect IL-23 secretion level, PBS is the control using PBS as an inducer, and LPS is verified by 200 ng / ml LPS stimulation; **, P < 0.01; B is immunofluorescence assay before and after treatment with clodronate liposomes, NC is the control group not treated with clodronate liposomes; MKO is the macrophage clearance group treated with clodronate liposomes; scale bar = 200 μm; C is ELISA to detect IL-23 secretion level under LPS stimulation after macrophage knockout, NC is the control group not treated with clodronate liposomes; MKO is the macrophage clearance group treated with clodronate liposomes; ***, P < 0.01;
[0036] Figure 4is the pathological phenotype after TGF-β induction for 48 hours; A is the morphology of organoids 48 hours after TGF-β modeling, scale bar = 500μm; B is the expression level of epithelial markers and mesenchymal markers analyzed by fluorescence quantitative PCR, β-CAT and EpCAM are epithelial cell markers, VIM and DES are mesenchymal cell markers; *, P < 0.05; **, P < 0.01; biological repeat n = 3; C is the proportion of CD86 positive cells analyzed by flow cytometry; CD86 is a marker of M1 macrophages; *, P < 0.05; biological repeat n = 3; D is EL ISA was used to analyze the content of inflammatory factors in the supernatant; **, P < 0.01; ***, P < 0.001; biological replicates n = 4; E was PAS staining quantitative analysis; the number of sections was n = 18, and n = 3 from duplicate wells; ***, P < 0.001; F was FD4 barrier permeability analysis; ***, P < 0.001; statistical sample n = 12 organoids; G was fluorescence quantitative PCR analysis of channel protein expression levels; **, P < 0.01; ***, P < 0.001; biological replicates n = 3; the samples used for analysis were all macrophage-containing colon organoids treated with PBS or 2.5 ng / ml TGF-β for 48 h;
[0037] Figure 5 A is the pathological phenotype after 96 hours of TGF-β induction; A is the organoid morphology after 96 hours of TGF-β modeling, scale bar = 500μm; B is the expression level of fibrosis markers analyzed by fluorescence quantitative PCR; α-SMA, COL1A1, FN1 and MYLK are intestinal fibrosis markers; *, P < 0.05; **, P < 0.01; ***, P < 0.001; biological replicates n = 3; C is the ELISA analysis of the content of supernatant fibrosis serum markers; **, P < 0.01; biological replicates n = 4; the analyzed samples were colon organoids treated with PBS or 2.5ng / ml TGF-β for 96 hours. DETAILED DESCRIPTION
[0038] It should be noted that the following non-limiting examples are provided to further illustrate the invention disclosed by the present invention. It will be appreciated by those skilled in the art that the technical representatives disclosed in the following examples have found methods that work well in the practice of the present invention, and therefore can be considered as examples of the patterns that constitute them. However, according to the present invention, it will be appreciated by those skilled in the art that many changes can be made to the disclosed particular aspects and still the same or similar results can be obtained without departing from the spirit and scope of the present invention.
[0039] Definitive endoderm: refers to the original development site of the main cells of internal organs such as the liver, small intestine, and large intestine in the early stage of embryonic development.
[0040] Derivatives of the hindgut (or derivatives of the anterior part of the gut): The gut refers to the strip of tissue that develops from the definitive endoderm in the early embryonic development. In vivo studies have shown that its anterior and posterior ends are composed of different progenitor cells, which can develop into different organs. Among them, the colon develops from the progenitor cell group near the posterior end of the gut, which is developmentally called the hindgut or posterior part of the gut.
[0041] Multi-lineage colon organoids: Refers to colon organoids with physiologically relevant cell types.
[0042] The method for inducing differentiation of macrophage-containing colon organoids of the present invention comprises the following steps:
[0043] 1. Inducing differentiation
[0044] Stage 1: Induced pluripotent stem cells produce endoderm and a small part of mesoderm
[0045] hPSCs are cultured in culture medium 1a and culture medium 1b for 1-2 days, preferably cultured in culture medium 1a for 1 day and cultured in culture medium 1b for 2 days;
[0046] Medium 1a was supplemented with BMP4 and ActA, and Medium 1b was supplemented with ActA and FGF2. Medium 1a and Medium 1b also included RPMI-1640 containing 2% (volume ratio) B27;
[0047] The concentration of BMP4 can be 20-50 ng / ml, within which the objectives of the present invention can be achieved, and specifically 50 ng / ml can be used;
[0048] The concentration of ActA can be 100-120 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0049] The concentration of FGF2 can be 5-10 ng / ml, and the objectives of the present invention can be achieved within this range. Specifically, 10 ng / ml can be used.
[0050] Stage 2: Production of hindgut derivatives
[0051] The cells are cultured in culture medium 2 for 6-7 days, specifically 6 days; culture medium 2 is supplemented with VEGF and SCF, the VEGF concentration can be 10-20 ng / ml, within this range the objectives of the present invention can be achieved, specifically 10 ng / ml can be used; the SCF concentration can be 5-15 ng / ml, within this range the objectives of the present invention can be achieved, specifically 5 ng / ml can be used.
[0052] At this stage, VEGF and SCF are important inducing molecules. Adding VEGF and SCF simultaneously to the existing culture medium can increase the expression of hematopoietic progenitor cell markers CD146 and CD43, and promote the differentiation of hematopoietic progenitor cells. The solution given in this embodiment is only a better one among many solutions.
[0053] More specifically, FGF4 and Wnt / β-CAT activator can be added to culture medium 2, and the Wnt / β-CAT activator is one of CHIR99021 and Wnt3a, but is not always limited thereto, and specifically can be preferably CHIR99021; the concentration of FGF4 can be 250-500 ng / ml, within this range the objectives of the present invention can be achieved, and specifically 500 ng / ml can be used; the concentration of Wnt / β-CAT activator can be 1-5 μM, within this range the objectives of the present invention can be achieved, and specifically 3 μM can be used.
[0054] To ensure the formation of macrophages, culture medium 2 also used hematopoietic cell culture medium StemPro-34 at a volume ratio of 21.25%-42.5%.
[0055] Specifically, Medium 2 contained 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12PLUS, and 42.5% (volume ratio) StemPro-34.
[0056] After differentiation into the mid-posterior derivatives of the intestinal tube with hematopoietic progenitor cells, the upper layer of 3D spheres was discarded and the lower layer of 2D cells was mechanically disrupted using a pipette tip to form clumps of 100-300um in size.
[0057] Mechanical crushing methods are:
[0058] 1) Scraping: Discard the old culture medium together with the upper 3D spheroids, add preheated DMEM / F12 culture medium, and place the pipette tip perpendicular to the culture well. Draw lines 10-15 times in the up-down and left-right directions to transfer the formed cell clusters and culture medium intact to the EP tube.
[0059] 2) Blow and break: Place the pipette against the bottom of the EP tube and gently blow 3-5 times to form cell clumps of 100-300uM in size.
[0060] After centrifugation and resuspension in pre-cooled Matrigel, the cells were coated in cell culture plates and differentiation was continued using medium S3.
[0061] Stage 3: Generation of macrophage-containing colon organoids
[0062] Sequentially culturing in medium 3a for 3-4 days and in medium 3b for 24-59 days (preferably 28-29 days), preferably culturing in medium 3a for 3 days and in medium 3b for 28 days;
[0063] Specifically, culture medium 3a contains additives BMP2, EGF, Wnt / β-CAT activator and StemPro-34 in a volume ratio of 21.25%-42.5%, and culture medium 3b contains additives EGF, VEGF, M-CSF, BMP inhibitor, Wnt / β-CAT activator and StemPro-34 in a volume ratio of 17.5-35%;
[0064] At this stage, VEGF and M-CSF are important inducing molecules. Adding VEGF and M-CSF simultaneously to the existing culture medium can promote the differentiation and formation of macrophages. The solution given in this embodiment is only a better one among many solutions.
[0065] In addition, the continuous addition of StemPro-34 into S2 and S3 and the concentration are also key to the present invention. The concentration scheme given in this example is only a better one among many schemes.
[0066] The concentration of BMP2 can be 50-150 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0067] The EGF concentration can be 50-150 ng / ml, within which the objectives of the present invention can be achieved, and specifically 100 ng / ml can be used;
[0068] The Wnt / β-CAT activator is one of CHIR99021 and Wnt3a, but is not always limited thereto, and may be preferably CHIR99021; the concentration of the Wnt / β-CAT activator may be 2-4 μM, within which the objectives of the present invention may be achieved, and specifically, the concentration in culture medium 3a is 3 μM, and the concentration in culture medium 3b is 2 μM.
[0069] The VEGF concentration can be 10-20 ng / ml, within which the objectives of the present invention can be achieved, and specifically 20 ng / ml can be used;
[0070] The concentration of M-CSF can be 10-20 ng / ml, within which the objectives of the present invention can be achieved, and specifically 10 ng / ml can be used;
[0071] The BMP inhibitor is one of LDN193189, NOG, and BML-275, but is not always limited thereto, and may be preferably LDN193189; the concentration of the BMP inhibitor may be 100-250 nM, and the objective of the present invention may be achieved within this range, and may be specifically 200 nM.
[0072] Specifically, medium 3a also contained 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12 PLUS, and 42.5% (volume ratio) StemPro-34;
[0073] Medium 3b also contained 2% (volume) B27, 0.5% (volume) N2, 80% (volume) DMEM-F12 Plus, and 17.5% (volume) StemPro-34.
[0074] 2. Serial passage and expansion of colon organoids
[0075] After the formed organoids are transferred to EP tubes, they are mechanically broken into 100-300 μm clumps using a pipette tip; after being coated with matrix gel again, they are pre-cultured with culture medium 3a for 1 day, and then cultured with culture medium 3b; they are subcultured every 7-10 days at a ratio of 1:5-1:10, and pre-culture is performed for each subculture.
[0076] The invention will be described in detail below with reference to the accompanying drawings and embodiments.
[0077] The relevant reagents used in the examples are shown in Tables 1 and 2, the relevant primers are shown in Table 3, and the relevant antibodies used are shown in Table 4.
[0078] Example 1 Preparation of macrophage-containing colon organoids of qualified quality
[0079] 1. Efficiently inducing differentiation of human iPS cells into macrophage-containing colon organoids
[0080] Stage 1: Induction of endoderm and a small amount of mesoderm (Days 1-3)
[0081] When the confluence of hPSCs reaches 80-95%, differentiation can be initiated.
[0082] 1.1 Day 1
[0083] The cells were cultured for 1 day in medium 1a, which contained the additives 50 ng / ml BMP4, 100 ng / ml ActA, and RPMI-1640 containing 2% (v / v) B27.
[0084] 1.2 Days 2-3
[0085] Culture was continued for 2 days in medium 1b containing supplements 100 ng / ml ActA, 10 ng / ml FGF2, and RPMI-1640 containing 2% (v / v) B27, with medium replacement daily.
[0086] Stage 2: Generation of midgut derivatives with hematopoietic progenitor cells (Days 4-9)
[0087] Culture was continued for 6 days in medium 2, which included additives 500 ng / ml FGF4, 3 μM CHIR99021, 10 ng / ml VEGF, 5 ng / ml SCF, and 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12PLUS, and 42.5% (volume ratio) StemPro-34, during which the medium was changed daily.
[0088] At the end of day 9, the upper 3D spheres were discarded and the lower 2D cells were mechanically disrupted using a pipette tip to form clumps of 100-300 μm in size.
[0089] Mechanical crushing methods are:
[0090] 1) Scraping: Discard the old culture medium together with the upper 3D spheroids, add preheated DMEM / F12 culture medium, and place the pipette tip perpendicular to the culture well to draw lines 10 times in the up-down and left-right directions to transfer the formed cell clusters and culture medium intact into the EP tube.
[0091] 2) Blow and break: Place the pipette against the bottom of the EP tube and gently blow 3-5 times to form cell clumps of 100-300uM in size.
[0092] After centrifugation and resuspension in pre-cooled Matrigel, the cells were coated in cell culture plates and differentiation was continued using medium S3.
[0093] Stage 3: Induction of macrophage-containing colonic organoids (Days 10-40)
[0094] 3.1: Day 10-12
[0095] The cells were cultured for 3 days in medium 3a, which included additives such as 100 ng / ml BMP2, 100 ng / ml EGF, 3 μM CHIR99021, and 2% (volume ratio) B27, 0.5% (volume ratio) N2, 55% (volume ratio) DMEM-F12 PLUS, and 42.5% (volume ratio) StemPro-34. The medium was not changed during this period.
[0096] 3.2: Day 13-40
[0097] Culture was continued for 28 days in medium 3b, which included the supplements 100 ng / ml EGF, 20 ng / ml VEGF, 10 ng / ml M-CSF, 200 nM LDN193189, 2 μM CHIR99021, as well as 2% (volume ratio) B27, 0.5% (volume ratio) N2, 80% (volume ratio) DMEM-F12 Plus, and 17.5% (volume ratio) StemPro-34.
[0098] During this period, the culture medium was changed every 3 days; by day 40, lineage specification was complete and macrophage-containing colon organoids were formed.
[0099] 2. In vitro continuous passage and expansion
[0100] After the organoids formed on the 40th day were transferred to EP tubes, they were mechanically broken into 100-300 μm clumps using a pipette tip; they were coated with matrix gel again, pre-cultured with culture medium 3a for 1 day, and then continued to use culture medium 3b; they were subcultured every 7-10 days at a ratio of 1:5-1:10, and pre-culture was performed for each subculture.
[0101] 3. Amplification product quality test
[0102] 1) Cell lineage analysis:
[0103] Expanded organoids were taken and lineage diversity was confirmed by flow cytometry.
[0104] Specifically, the flow cytometry method is as follows: the amplified product is digested and dispersed into single cells using TrypLE, and fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton, and blocked with 5% normal donkey serum. After that, the cell number is analyzed using a flow cytometer after labeling and staining based on specific marker antibodies.
[0105] Interpretation of results: When the organoids have colon epithelial cells, mesenchymal cells and intestinal resident macrophages, they are considered to have passed the test. Specifically, these cells include: STAB2 + Colonic epithelial cells, MUC2 + Goblet cells, VIM + Mesenchymal cells and CD68 + Macrophages.
[0106] 2) Macrophage inflammation-mediated function assay:
[0107] After 24 h of stimulation with 200 ng / ml LPS, the secretion of inflammatory factors in the supernatant was measured by ELISA.
[0108] When the level of inflammatory factors increases significantly, it is considered as passing the test.
[0109] Specifically, the optional inflammatory factors include IL-23, IL-6, TNF-α, IL-1β, etc.
[0110] Example 2 Inflammatory Bowel Disease and Fibrosis Simulation
[0111] 1. IBD simulation
[0112] After quality identification, TGF-β was used to induce for 48 hours, and the IBD pathological phenotype of the organoids was analyzed. The concentration of TGF-β can be 2-10 ng / ml, and the objectives of the present invention can be achieved within this range. Specifically, 2.5 ng / ml can be used in this embodiment.
[0113] The control group consisted of macrophage-containing colon organoids treated with PBS for 48 h.
[0114] IBD pathological phenotype analysis items can be selected:
[0115] 1) Macrophage polarization: M1 macrophage markers such as CD86 and CD80 can be detected by flow cytometry;
[0116] 2) Increased inflammation level: Inflammatory factors such as IL-23, IL-6, TNF-α, IL-1β, etc. can be measured by ELISA;
[0117] 3) Reduced mucus content: PAS mucus staining and ELISA for MUC2 detection can be selected;
[0118] 4) Intensified epithelial-mesenchymal transition: epithelial markers such as ECAD and β-CAT, and mesenchymal markers such as VIM and DES can be analyzed by fluorescent quantitative PCR or immunostaining;
[0119] 5) Pathological indicators such as intestinal barrier damage: Channel protein markers such as CLDN can be analyzed through barrier permeability experiments or fluorescence quantitative PCR.
[0120] 2. Fibrosis simulation:
[0121] Modeling group: After continuous induction of organoids for 96 hours, the fibrosis pathological phenotype of the organoids can be analyzed.
[0122] Control group: macrophage-containing colon organoids treated with PBS for 96 h.
[0123] The analysis items can be selected:
[0124] 1) ECM accumulation: markers such as α-SMA, COL1A1 / 3, FN1, PDGFRα / β, and MYLK can be analyzed by quantitative PCR or immunostaining;
[0125] 2) Increased serum markers of fibrosis: Markers such as PIIINP can be measured by ELISA.
[0126] Results and Analysis:
[0127] 1. Follow the technical process ( Figure 1 ), after induction of differentiation and passage expansion to P3, the amplified product was taken for cell lineage identification, such as Figure 2 Flow cytometry results showed that organoids have STAB2 + Colonic epithelial cells, MUC2 + Goblet cells, VIM + Mesenchymal cells and CD68 + Macrophages; indicating that the organoids have lineage diversity after passaging.
[0128] like Figure 3 The results of macrophage function analysis showed that after 24h of stimulation with 200ng / ml LPS, the IL-23 content in the supernatant increased significantly ( Figure 3 A). To confirm that the inflammatory response is mainly mediated by macrophages, the macrophages were cleared after treatment with the macrophage clearing agent clodronate liposomes ( Figure 3 B); when stimulated by LPS, inflammatory factors were significantly reduced ( Figure 3 C).
[0129] 2. If Figure 4 A Bright field morphological analysis showed that compared with the control group, the lumen of the TGF-β modeled organoids shrank and solidified, the number of peripheral crypt structures was significantly reduced, and a small amount of cell death was visible at the edge. These observations all indicate that damage has occurred.
[0130] Flow cytometry analysis confirmed that CD86 + The proportion of M1 macrophages increased significantly, indicating that M1 macrophage polarization occurred ( Figure 4 C), accompanied by a significant increase in the levels of inflammatory factors TNF-α and IL-23 in the supernatant, indicating an inflammatory response ( Figure 4 D).
[0131] The results of fluorescence quantitative PCR showed that compared with the control group, the expression levels of epithelial cell markers β-CAT and EpCAM were significantly reduced, and the expression levels of mesenchymal cell markers VIM and DES were significantly increased, showing an obvious epithelial-mesenchymal transition effect ( Figure 4 B).
[0132] The results of PAS staining analysis showed that the positive area of the modeling group was significantly reduced, indicating that the mucus content was reduced ( Figure 4E); The results of the epithelial barrier integrity experiment showed that 48h TGF-β induction significantly reduced the permeability of FD4 ( Figure 4 F); At the same time, the expression levels of channel proteins such as CLDN1 and CLDN3 were significantly reduced ( Figure 4 G); These results consistently demonstrated that the epithelial barrier was severely damaged.
[0133] 3. After the modeling time was extended to 96 hours, there was no distinguishable crypt structure around the organoid, the inner cavity was completely solidified, the overall structure collapsed, and there was obvious cell death ( Figure 5 A).
[0134] The quantitative PCR results showed that compared with the control group, the fibrosis markers α-SMA, COL1A1, FN1, and MYLK in the modeling group were consistently upregulated ( Figure 5 B); The results of ELISA in the culture supernatant showed that the content of PIIINP increased significantly, proving the successful induction of fibrotic phenotype ( Figure 5 C).
[0135] In summary, the method described in the present invention can induce a series of IBD pathological phenotypes such as macrophage polarization, inflammatory response, epithelial-mesenchymal transition, barrier damage, etc. within 48 hours; and progress to fibrosis within the next 4 days, showing clinical pathological characteristics such as increased serum markers and collagen deposition. This disease model not only has a human genetic background, but also can quickly realize multi-scale pathological simulation of IBD, which is suitable as a new generation of research tools for disease analysis and drug efficacy screening.
[0136] Table 1 Reagent list
[0137]
[0138] Table 2 Corresponding names of reagents
[0139]
[0140] Table 3 Primer list
[0141]
[0142] Table 4 Antibody list
[0143]
[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for accurately simulating inflammatory bowel disease and fibrosis in vitro, characterized in that: The method comprises the following steps: 1) Construction of macrophage-containing colon organoids Induce pluripotent stem cells to differentiate into the middle and posterior derivatives of the intestinal tube with hematopoietic progenitor cells, then select the lower layer 2D cells for mechanical disruption, and then encapsulate them in Matrigel and use medium 3a and medium 3b to continue differentiation to form colon organoids; The obtained organoids were then transferred to EP tubes and mechanically broken, and then coated with matrix gel again, and then pre-cultured with culture medium 3a, and then continued to be cultured with culture medium 3b, and subcultured every 7-10 days, with pre-culture operations performed for each subculture; the expanded and cultured organoids were then tested to verify that the organoids had both colon epithelial cells, mesenchymal cells and intestinal resident macrophages, and the inflammation-mediating function of macrophages was verified; Among them, the organoids were pre-cultured in culture medium 3a for 1-2 days after mechanical disruption; culture medium 3a included BMP2, EGF, Wnt / β-CAT activator and StemPro-34, and culture medium 3b included EGF, BMP inhibitor, Wnt / β-CAT activator, VEGF, M-CSF and StemPro-34; the concentration of BMP2 was 50-150ng / ml, the concentration of EGF was 50-150ng / ml, the concentration of Wnt / β-CAT activator was 2-4μM, the concentration of BMP inhibitor was 100-250nM, the concentration of VEGF was 10-20ng / ml, and the concentration of M-CSF was 10-20ng / ml; the volume ratio of StemPro-34 in culture medium 3a was 21.25%-42.5%, and the volume ratio in culture medium 3b was 17.5-35%; 2) Inflammatory bowel disease and fibrosis simulation 2.1) IBD simulation Induce the organoids obtained in step 1) with TGF-β for 48-72h, with a TGF-β concentration of 2-10ng / ml, and perform IBD pathological phenotype analysis on the organoids to verify the IBD model; 2.2) Fibrosis simulation After continuous induction for 96-120 hours, the organoids were analyzed for fibrosis pathological phenotype to verify the obtained fibrosis model.
2. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 1, characterized in that: In step 1), organoids are characterized by flow cytometry or immunofluorescence staining to confirm lineage diversity.
3. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 1, characterized in that: In step 1), the method for verifying the inflammatory mediating function of macrophages is: after stimulating the organoids with 200 ng / ml LPS for 24 hours, the secretion of inflammatory factors in the supernatant is measured by ELISA.
4. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 3, characterized in that: Inflammatory factors include one or more of IL-23, IL-6, TNF-α, and IL-1β.
5. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 1, characterized in that: The pathological phenotype of IBD includes one or more of the following indicators: macrophage polarization, increased inflammation, decreased mucus content, enhanced epithelial-mesenchymal transition, and impaired intestinal barrier; The fibrotic pathological phenotype includes one or two of the following indicators: ECM accumulation and increased serum fibrosis markers.
6. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 5, characterized in that: Macrophage polarization can be analyzed by detecting M1 macrophage markers using flow cytometry; Increased inflammation levels can be analyzed by measuring inflammatory factors through ELISA; Reduced mucus content can be analyzed by PAS mucus staining and ELISA for MUC2; The epithelial-mesenchymal transition can be aggravated by analyzing epithelial and mesenchymal markers through quantitative PCR or immunostaining; Intestinal barrier damage can be detected by analyzing channel protein markers through barrier permeability experiments or fluorescence quantitative PCR.
7. The in vitro precise simulation method of inflammatory bowel disease and fibrosis according to claim 5, characterized in that: ECM accumulation can be analyzed by quantitative PCR or immunostaining for one or more of the markers α-SMA, COL1 / 3, FN1, PDGFRα / β, and MYLK; Elevated serum markers of fibrosis can be measured by ELISA for the marker PIIINP.
Citation Information
Patent Citations
Application of miR-200b in the preparation of drugs for treating inflammatory bowel disease and fibrosis
CN102277427A
Construction method of colon-like organ with immune cells
CN118240750A
